Anixa Biosciences, Inc.
ANIX
Rank in Stocks
#19290
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to... Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Share Price
$3.16
Last synced: 2026-11-09
Market Cap
$109.85M
Change (1 day)
-0.47%
Change (1 year)
-31.30%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anixa Biosciences, Inc. (ANIX)
Category
Healthcare
Operating Margin for Anixa Biosciences, Inc. (ANIX)
Operating Margin as of November 2026 TTM: 0.00%
According to Anixa Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Anixa Biosciences, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -5,243.33% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -2,565.56% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -4,756.00% | 286.04% |
| 2018 | -1,232.01% | -26.49% |
| 2017 | -1,676.02% | 11.51% |
| 2016 | -1,503.00% | 14,620.86% |
| 2015 | -10.21% | -92.58% |
| 2014 | -137.54% | -93.25% |
| 2013 | -2,036.17% | 362.93% |
| 2012 | -439.84% | -12.25% |
| 2011 | -501.23% | -30.22% |
| 2010 | -718.27% | 3.59% |
| 2009 | -693.35% | 138.83% |
| 2008 | -290.31% | -74.27% |
| 2007 | -1,128.14% | -24.77% |
| 2006 | -1,499.58% | 47.68% |
| 2005 | -1,015.44% | 49.21% |
| 2004 | -680.54% | -46.71% |
| 2003 | -1,277.15% | 1,902.12% |
| 2002 | -63.79% | -70.08% |
| 2001 | -213.17% | -38.29% |
| 2000 | -345.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Anixa Biosciences, Inc.'s operating margin
What was Anixa Biosciences, Inc.'s operating margin in 2025?
In 2025, Anixa Biosciences, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Anixa Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Anixa Biosciences, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-5,243.33%).
How does Anixa Biosciences, Inc.'s operating margin compare with similar companies?
Anixa Biosciences, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.